Analytical Data
-
Gene name
KCNA3
- Application
-
Alternative Names
HGK5
-
Species
Human
-
Source
HEK293
-
Tag
Strep;His;GFP
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22001
-
Expression Region
M1-V575
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCNA3, also known as the voltage-gated potassium channel KCa3.1, plays a critical role in various physiological processes, including neuronal excitability, muscle contraction, and cellular signaling. As a member of the shaker-like potassium channel family, KCNA3 is responsible for the repolarization phase of action potentials in excitable cells. Its dysfunction has been implicated in several pathophysiological conditions, such as cancer, immune disorders, and cardiovascular diseases, making it a target for therapeutic interventions. Recent advances in molecular biology have facilitated the recombinant expression of KCNA3 in various systems, allowing for deeper functional analysis and structural studies. This has opened new avenues for drug discovery, particularly in identifying ion channel modulators that can selectively target KCNA3. Furthermore, the study of its complex regulation, including post-translational modifications and interactions with ancillary subunits, is essential for understanding its role in health and disease. Thus, the investigation of KCNA3 recombinant proteins not only provides insights into potassium channel biology but also holds significant potential for developing novel therapeutic strategies.
